| Adakveo (crizanlizumab) | Hydroxyurea (trial 6 months) | Must document 6‑month hydroxyurea trial or intolerance/contraindication; coverage duration 2 years; submit Medicare Part B drug request form. |
| Alyglo (IVIG) | Two preferred IVIG products (examples: Gammagard Liquid, Gamunex‑C, Privigen) | Part B vs Part D determination required; must try two preferred IVIGs prior to Part B IVIG coverage; provide medical records. |
| Alymsys (bevacizumab biosimilar) | Mvasi AND Zirabev | Must try both biosimilars (Mvasi and Zirabev) prior to Avastin (J9035); criteria applied consistent with LCD L37205; coverage up to 1 year. |
| Avastin (bevacizumab) — J9035 chemotherapy | Mvasi AND Zirabev | Chemotherapy J9035 only; must document trials of Mvasi and Zirabev before Avastin; coverage duration up to 1 year; use Oncology drug request form. |
| Aveed (testosterone undecanoate) | Generic intramuscular testosterone (cypionate or enanthate) AND generic topical testosterone | For hypogonadism/gender dysphoria pathways: must document trials/failures of generic IM and topical testosterone, two morning total testosterone measurements on separate days <300 ng/dL (or below lab reference), and clinical signs; coverage 2 years. |
| Azmiro (testosterone formulation) | Generic testosterone cypionate trial | Prior trial and failure of generic testosterone cypionate required; must supply two morning total testosterone measurements <300 ng/dL and clinical signs; coverage 2 years. |
| Beizray / Beizray‑Albumin (docetaxel formulations) | Generic docetaxel (Taxotere, HCPCS J9171) | Must first try generic docetaxel (J9171) prior to Beizray/Beizray‑Albumin; provide medical records; coverage duration 1 year. |
| Boruzu (bortezomib) | Generic bortezomib injectable (e.g., HCPCS J9049 or J9041) | Step therapy requires trial of a generic bortezomib product prior to Boruzu; provide prior‑therapy documentation; coverage up to 1 year. |
| Aukelso (denosumab biosimilar) | Wyost, Xtrenbo, AND Bilprevda | Must try all three prior to Aukelso; biosimilar provisionally interchangeable with Xgeva; coverage up to 2 years. |
| Bomyntra (denosumab biosimilar) | Wyost, Xtrenbo, AND Bilprevda | Must first try Wyost, Xtrenbo, and Bilprevda before Bomyntra; provide medical records; coverage up to 2 years. |
| Bosaya (denosumab biosimilar) | Jubbonti, Enoby, AND Bildyos | Must first try listed preferred denosumab/alternatives prior to Bosaya; provide documentation; coverage per FDA labeling. |
| Cimzia (certolizumab) | Failure of TWO agents (e.g., preferred adalimumab product AND another listed agent such as Rinvoq, Skyrizi, Tyenne, Cosentyx, Otezla, Xeljanz/XR, Yesintek/Selaradi or Enbrel) | Step therapy requires failure/intolerance of two specified agents; prescriber specialist or consultation; coverage duration 2 years. |
| Cinqair (reslizumab) | ICS/LABA plus 1 other controller (prior controller therapy) — and biomarker criteria | For severe eosinophilic asthma: eosinophils ≥150 cells/µL at start OR ≥300 cells/µL in prior 12 months; must have tried appropriate inhaled controller regimen; provide weight and records. |
| Cinryze (C1‑esterase inhibitor) | Haegarda | Must first try Haegarda before Cinryze; provide medical records documenting prior therapies and responses; coverage duration 2 years. |
| Conexxence (C1‑esterase reference biosimilar) | Jubbonti, Enoby, AND Bildyos | Must first try Jubbonti, Enoby, and Bildyos prior to Conexxence; provide prior‑therapy documentation; coverage up to 2 years. |
| Cosentyx IV (secukinumab IV) | Avsola OR Renflexis OR Simponi Aria | Must first try Avsola, Renflexis, or Simponi Aria prior to Cosentyx IV; not to be used in combination with other biologics, Otezla, or JAK inhibitors; prescriber specialist; coverage 2 years. |
| Docivyx (docetaxel) | Generic docetaxel (Taxotere, J9171) | Must first try generic docetaxel (J9171) prior to Docivyx; submit Medicare Part B (Non‑Oncology) drug request form; coverage duration 1 year. |
| Durysta (bimatoprost implant) | Two topical prostaglandin analogs (latanoprost, bimatoprost, travoprost) | Must try TWO topical prostaglandin analogs prior to Durysta implant; provide documentation of trials and responses; dosing per FDA labeling. |
| Emblaveo (aztreonam‑avibactam) | All other generic susceptible antibiotics per culture/sensitivity (or empiric guidance) | Designated Part B Step Therapy drug; must try other appropriate antibiotics per culture/sensitivity; prescriber infectious disease specialist or consult; approval limited to 6 months. |
| Enjaymo (sutimlimab) | Rituximab‑containing regimen (documented trial and failure) | Document trial and failure of a rituximab‑containing regimen prior to Enjaymo; provide transfusion history, baseline labs, weight; initial 6 months, reauth 12 months with documented benefit. |
| Entyvio (vedolizumab) | Avsola OR Renflexis | Must first try Avsola or Renflexis prior to Entyvio; provide medical records documenting prior therapies and responses; not used with other biologics/Otezla/JAK inhibitors; initial 1 year, reauth 2 years. |
| Epogen (epoetin alfa) — non‑ESRD Part B requests | Procrit AND Retacrit | Non‑ESRD Part B requests must first try Procrit and Retacrit per LCD L34633; provide documentation; coverage up to 2 years. |
| Erzofri (paliperidone long‑acting) | Invega Sustenna OR Invega Trinza OR Invega Hayfera | Must first try one of the specified Invega products prior to Erzofri; step therapy applied per guidance. |
| Evenity (romosozumab) | Oral bisphosphonate (alendronate, risedronate, ibandronate) AND either zoledronic acid or Jubbonti — OR meet very high fracture risk criteria | Must meet one pathway: prior bisphosphonate plus zoledronic acid/Jubbonti failure or very high fracture risk (T‑score thresholds); cumulative use limited to 12 months lifetime; prescriber endocrinologist; coverage 12 months per lifetime. |
| Evkeeza (evinacumab) | Repatha (prior trial) — except children 5–9 years where trial not required | Must first try Repatha prior to Evkeeza (trial not required in children 5–9 yrs); provide medical records documenting prior therapies and responses; coverage 2 years. |
| Casgevy (gene therapy) | N/A (one‑time gene therapy) — must document prior standard therapies such as hydroxyurea or alternatives for SCD; transfusion history for beta thalassemia | Requires comprehensive documentation (genotype confirmation for SCD or transfusion dependence for beta thalassemia), prior therapy history, organ function and HSCT eligibility; limited to one lifetime dose; authorization 6 months; prior HSCT or prior gene therapy excludes coverage. |